Immutep Limited (NASDAQ:IMMP - Get Free Report) shares passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $1.99 and traded as high as $2.05. Immutep shares last traded at $1.95, with a volume of 104,357 shares trading hands.
Analyst Upgrades and Downgrades
Separately, Robert W. Baird boosted their price objective on shares of Immutep from $6.00 to $7.00 and gave the company an "outperform" rating in a research note on Friday, November 15th.
Check Out Our Latest Research Report on IMMP
Immutep Trading Up 4.6 %
The company has a quick ratio of 18.25, a current ratio of 18.25 and a debt-to-equity ratio of 0.01. The firm has a 50 day moving average price of $1.99 and a two-hundred day moving average price of $2.16.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the business. XTX Topco Ltd purchased a new position in shares of Immutep in the 2nd quarter valued at $26,000. XY Capital Ltd acquired a new stake in Immutep in the 2nd quarter valued at $105,000. Finally, Meridian Wealth Management LLC raised its position in Immutep by 4.5% in the third quarter. Meridian Wealth Management LLC now owns 398,450 shares of the biotechnology company's stock valued at $881,000 after purchasing an additional 17,250 shares during the period. 2.32% of the stock is owned by institutional investors and hedge funds.
About Immutep
(
Get Free Report)
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.
Further Reading
Before you consider Immutep, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immutep wasn't on the list.
While Immutep currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
